Deja Vu?Almost exactly one-year ago NDRA received this same form 8-K "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing." *Shortly after recieving this notice, NDRA's Price shot up dramatically.
In September, ENDRA Life Sciences is planning to present the final results of the #Robarts study in conjunction with the upcoming EASL-NAFLD Summit in Seville, Spain.
Pattern is very similar to last year's notification.
Disclosure: I am long NDRA. This is not a note to buy or sell. Please do your own Homework before investing.
Biotech
(Nasdaq: CODX) Bullish signal - GOLDEN CROSSThis could be the next NASDAQ Biotech ready to move in a big way, here's why...
(Nasdaq: CODX) displaying the Holy grail of Bullish signals - a GOLDEN CROSS.
The 50 Day EMA just crossed the 200 Day EMA, which most of you know by now is a bullish signal that indicates a potential breakout is on the Horizon.
Here Is Another Potential "Breakout Catalyst" In Play
Wall Street Analysts at H.C. Wainwright & Maxim Group have both given Co-Diagnostics (Nasdaq: CODX) Buy rating with a $2.00 Price Target, almost double its price at Fridays close, suggesting the stock has a potential upside of +80%.
Cronos Group Inc. (CRON) long.All description on the chart.
Please, don't forget to like and follow.
Thank you.
Photocure $PHO.OL stock pullback after Q2 is chance to buyPhotocure $PHO.OL OSL:PHO presented Q2 2019 numbers today, with most numbers landing very close to expectations.
Webcast: webtv.hegnar.no
Press release: newsweb.oslobors.no
Armchair Healthcare podcast interview with CEO Dan Schneider: twitter.com
Bearish Butterfly SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking to start a position.
According to the bearish setup SGEN should find 50 -618 retracement before next ER bringing SGEN down to around the $69 mark. As I have outlined in this setup, SGEN is still making higher lows on long-term chart and after retracing back to $69, should see continue uptrend to ~$84 (assuming another positive ER or catalyst).
Tip - Even if you rely mostly on company fundamentals, you should be aware of support/ resistance levels.
Please Follow, like, comment, and share so I can continue finding awesome trades. Thank you in advance >+)
Find me on Twitter or Instagram @VolatilityWatch
Disclosure: I do not own a position in SGEN. I may buy/sell within the next 72 hours. This is not a note to buy or sell, please do your homework before investing.
G1 Therapeutics RALLYEarnings/News
Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co
Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
$ATOS Is A Good Risk/Reward PlayAbout Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.
$MACK Merrimack Pharmaceuticals Inc Heading HigherShareholders of $MACK are getting a $20 million special dividend.
The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following the payment date. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. Based on the current number of shares outstanding, the special dividend will be approximately $1.50 per common share; this amount may vary based on the number of outstanding shares as of the record date.
"The authorization of a special dividend higher than the range that we had initially estimated is an important step in implementing the strategic plan that we announced on May 30, 2019 and reflects our success in restructuring the Company and the recent closing of the sale of certain programs to 14ner Oncology, Inc.," said Gary Crocker, Chairman of Merrimack's Board of Directors. "Our remaining cash balance is anticipated to support operations into 2027, when we estimate the longest-term potential Ipsen milestone may be achieved."
About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $455.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017 and up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to 14ner Oncology, Inc. in July 2019. The Company is seeking potential acquirers for its remaining preclinical and clinical assets.
Why is the $20 million special dividend significant?
Because $MACK has a market cap of just $80 million.
$MACK looks to be a buy and hold.
As always, use protective stops and trade with caution.
Good luck to all!
EnWave: Buy the Lows and Go Long!EnWave will likely be one of the key hidden gems in the biotechnological industry and will continue to gain volume as time progresses.
Their company focuses on a multitude of revenue streams for dehydration techniques (patented) and has several revenue streams including royalty bearing and selling their equipment to other companies.
This is one of the most stable dollar stocks on the market right now as a result of their market cap to stock value ratio, as well as, given their stock price, they are actually on the verge of profitability before 2020.
As time progresses they continue to sign deals with international companies around the world and the stock value will only continue to grow.
They focus strongly in (but not exclusively with) the cannabis dehydration market; while cannabis has been hit brutally hard from CannTrust's scandal recently, I am eyeing a rebound beginning September for the cannabis industry, and even though EnWave continued to increase during the downturn, I am looking at a breakout in Q4 2019 to 3.50-4.00.
Just like the semis got demolished and made a roaring rebound, I expect the same in Q4 of 2019 of cannabis and will likely be a leading sector, although most stocks likely won't make any new highs.
Remember: Dollar stocks never move linearly and always have several retracements. Never buy dollar stocks all at once - never sell them all at once, even when breakouts occur. However, go long in EnWave!
- zSplit
AMGN attempting trend line breakout ahead of earningsAmgen is attempting a breakout above its one-month downward trend line this morning. I will wait to enter until I see a change in volume. Currently there's bearish divergence on the volume profile, which suggests that this may correct downward before confirming the breakout.
Amgen reports earnings tomorrow, and has a positive earnings surprise prediction from Zacks. Amgen has beaten analyst estimates 7 of 8 quarters in the last 2 years. The company's recent price weakness and great valuation (15.8% below the average analyst price target) makes it a good candidate for a pop on an earnings beat.
Triangle formation Immunovia- BLUE - Possible stock price improvement, based on the theory of triangles.
- YELLOW - Triangle hypotenuse that can't be crossed if formation is to be completed.
- RED - Triangle roof that can give a buy signal if crossed.
Wanted to share with you what I found in the chart. This is not a advice to invest. Plz comment if you disagree or want to add something :)
Biotech - Bearish BreakoutPotential downside breakout for biotech. Still too early to confirm whether it's real or a fake, keep an eye on this one.
Entered 25% position so far, will look to add more if further confirmation appears.
Biogen ascending triangleBiogen has formed an ascending triangle. With strong earnings and a guidance upgrade, the catalysts favor upward breakout. However, certain aspects of Biogen's business are struggling and face increasing competition, so the stock could also fall. I will play oscillations within the triangle by buying and selling crossovers of the green line, with stop losses in place. I will also play the eventual breakout.
My fans asked and I obliged, but LABU ain't lookin' greatOne of my followers asked (and this has never happened before) for me to comment on LABU. I was touched by the request and so I have responded, and this after having a website which I shut down with 10,000 hits a month never once did anyone ask me to comment on a stock. My strength has always been analysis and dissection so I am happy to oblige.
LABU isn't looking very strong. Its currently trending downwards, it's below the SMA line which I used for my day trades and it has a lot of overhead resistance. For a while it looked like it was in a condensing pattern and has broken down and then decided to move sideways. These are not adjectives and verbs you use to describe a stock that's in a good place. The odd thing, going to about two years is that the stock is inside an even larger condensing pattern that must be watched closely. Its currrently holding just above support and if this breaks a big slide could be witnessed!
Zynerba Pharmaceuticals in upward channelZynerba Pharmaceuticals has been surging since it got added to the Russell 2000 and 3000 indices. It is in an upward channel, just broke trendline resistance, and looks strong on the indicators, including high buying volume. It will meet short-term resistance around 16.47. Look for a break above that level on volume.
